Effect of IL-2 on primary hepatic carcinoma and its potential clinical value

Abstract

Pang Jing, Deng Zhihua. Effect of IL-2 on primary hepatic carcinoma and its potential clinical value[J]. Journal of International Oncology, 2015, 42(12): 939-941.

［1］ Teng MW, von Scheidt B, Duret H, et al. AntiIL23 monoclonal antibody synergizes in combination with targeted therapies or IL2 to suppress tumor growth and metastases［J］. Cancer Res, 2011, 71(6): 2077-2086. ［2］ Xu HM. Th1 cytokinebased immunotherapy for cancer［J］. Hepatobiliary Pancreat Dis Int, 2014, 13(5): 482-494. ［3］ Weiss JM, Subleski JJ, Back T, et al. Regulatory T cells and myeloidderived suppressor cells in the tumor microenvironment undergo Fasdependent cell death during IL2/aCD40 therapy［J］. J Immunol, 2014, 192(12): 5821-5829. ［4］ Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms and implications to cancer immunotherapy［J］. Ann NY Acad Sci, 2013, 1284: 1-5. ［5］ Kakita N, Kanto T, Itose I, et al. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-)FOXP3(-) T cells［J］. Int J Cancer, 2012, 131(11): 2573-2583. ［6］ Xiao G, Deng A, Liu H, et al. Activator protein 1 suppresses antitumor Tcell function via the induction of programmed death 1［J］. Proc Natl Acad Sci USA, 2012, 109(38): 15419-15424. ［7］ Kozowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines［J］. Gene, 2013, 525(2): 200-207. ［8］ Yang JY, Li X, Gao L, et al. Cotransfection of dendritic cells with AFP and IL2 genes enhances the induction of tumor antigenspecific antitumor immunity［J］. Exp Ther Med, 2012, 4(4): 655-660. ［9］ Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro［J］. J Immunol, 2009, 183(12): 8286-8294. ［10］ Tomova R, Antonov K, Ivanova A, et al. Lowdose IL2 therapy reduces HCV RNA and HBV DNA: case report［J］. Anticancer Res, 2009, 29(12): 5241-5244. ［11］ Zhang X, Wei HX, Rui S, et al. Opposite effects of high and low doses of interleukin2 on T cellmediated hepatitis in mice (interleukin2 on hepatitis)［J］. Hepatol Int, 2010, 4(3): 641-648. ［12］ Su K, Chen F, Yan WM, et al. Fibrinogenlike protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL2 and IFNgamma［J］. World J Gastroenterol, 2008, 14(39): 5980-5989. ［13］ Cabrera R, Ararat M, Cao M, et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)［J］. Dig Dis Sci, 2010, 55(2): 484-495. ［14］ Chen JD, Xiong YQ, Dong K, et al. Clinical significance of joint detection of serum VEGF, SIL2R and HGF in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy［J］. Asian Pac J Cancer Prev, 2014, 15(11): 4545-4548. ［15］ Seidler S, Zimmermann HW, Weiskirchen R, et al. Elevated circulating soluble interleukin2 receptor in patients with chronic liver diseases is associated with nonclassical monocytes［J］. BMC Gastroenterol, 2012, 12: 38. ［16］ Cabrera R, Ararat M, Eksioglu EA, et al. Influence of serum and soluble CD25 (sCD25) on regulatory and effector Tcell function in hepatocellular carcinoma［J］. Scand J Immunol, 2010, 72(4): 293-301. ［17］王鹤, 邓志华. 乙肝病毒衣壳运载体甲胎蛋白启动子驱动的白细胞介素2在肝癌细胞中的靶向表达［J］. 肿瘤研究与临床, 2014, 26(1): 20-23.

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Li Jiaxuan, Feng Yinglu.Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.
[6]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[7]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng.Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer[J]. Journal of International Oncology, 2022, 49(10): 592-596.
[8]	Di Weihua, Zhao Xuemei.Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.
[9]	Du Jiahang, Chen Dong, Chen Yaoting.Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.
[10]	Han Baojun.Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of International Oncology, 2021, 48(7): 415-419.
[11]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.
[12]	Xiong Lin, Zhang Xiuyun, Zhang Xiaoyu, Li Yue, Xu Ximing.IWR-1-endo affects the migration and proliferation of hepatocarcinoma cells by inhibiting the Wnt pathway[J]. Journal of International Oncology, 2021, 48(12): 711-715.
[13]	Liu Junguo, Zhang Jinjuan, Wang Yijun.Clinical application progress of variations in the technique of liver partition from ALPPS[J]. Journal of International Oncology, 2020, 47(8): 492-495.
[14]	Xin Ruiqiang, Song Xiaoping, Zhang Fan, Sun Ying, Wang Tao, Sun Wei.Mechanism of SUMO regulating XBP1 mediated endoplasmic reticulum stress on the progression of liver cancer[J]. Journal of International Oncology, 2020, 47(7): 397-403.
[15]	Zhao Chuanxi, Zhu Tingting, Liu Mingguo, Cao Lili.Advances of Krüppel-like factors in hepatocellular carcinoma[J]. Journal of International Oncology, 2020, 47(2): 119-122.

Effect of IL-2 on primary hepatic carcinoma and its potential clinical value

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments